Floatz logo

Nivolumab

Metastatic Kidney Carcinoma

Fondazione Policlinico Universitario Agostino Gemelli IRCCSmonoclonal_antibodyPhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

41 Active assets in the Metastatic Kidney Carcinoma cohort.

Asset / SponsorPhaseRating
Bms-907351
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
Ipilimumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
Pembrolizumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
LENVATINIB
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3B
Arestin
RenJi Hospital
Phase 3B

View all 50 →

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →
lung adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →